Literature DB >> 9510120

Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.

M Trovato1, D Villari, L Bartolone, S Spinella, A Simone, M A Violi, F Trimarchi, D Batolo, S Benvenga.   

Abstract

We have examined the coexpression of hepatocyte growth factor (HGF) and its receptor (HGF-R or c-met) in an archival series of 63 paraffin-embedded thyroid specimens plus one lymph node metastasis. By immunocytochemistry, we found undetectable expression of both the ligand and the receptor in 10 normal thyroids and 9 nonpapillary malignant nodules [5 follicular carcinomas, 1 poorly differentiated (insular) carcinoma, 3 undifferentiated (anaplastic) carcinomas]. Of 10 non-neoplastic nodules (colloid nodules) and 17 benign neoplastic nodules, 3 of 10 colloid nodules, 2 of 10 follicular adenomas, and 2 of 7 oncocytic adenomas showed a weak but distinct staining (1+ score in a scale from 0 to 4+) of both HGF and c-met in a modest proportion of cells (1% to 3%). In these 7 cases, expression of HGF was always stromal and expression of c-met limited to the membrane of the follicular cells. Of 3 malignant nodules derived from aberrant growth of the parafollicular C cells (medullary thyroid cancer or MTC), 2 were positive (6% of cells). In these 2 cases, the expression of HGF (3+) was not stromal, but in both the membrane and cytoplasm of the parafollicular cells, while that of c-met (3+) was restricted to the membrane. In contrast to all of the above, of 14 papillary carcinomas (PTC) encompassing 5 histological variants (conventional; follicular; oncocytic; with foci of solid growth; diffuse sclerosing) plus 1 neck lymph node metastasis of 1 conventional PTC, 12 (86%) expressed HGF, and 13 (93%) expressed c-met. With the exception of 2 negative cases, HGF was detected in 15% to 46% of the cells. The highest percentage (46%) pertained to conventional PTC cases with abundant peritumoral lymphocyte infiltration, indicating that some lymphokine(s) may recruit PTC cells for HGF expression in a paracrine fashion. With the exception of one negative case, c-met was found in 43% to 80% of the cells, both at levels from intense (3+) to very intense (4+). The immunostaining for HGF was stromal in 25%, membranous in 8%, cytoplasmic in 8%, and both membranous and cytoplasmic in 59% of the PTC-positive cases. The immunostaining for c-met was membranous in 43% and both membranous and cytoplasmic in 57% of the PTC-positive cases. In the lymph node metastasis and in the diffuse sclerosing variant of PTC (the most aggressive variant), the coexpression of HGF/c-met was lost, in that only c-met was expressed on membranes in both cases. We conclude that the HGF/c-met system is activated (by overexpression of both components) in the vast majority of PTC. In most PTC the interaction of HGF and its receptor (c-met) is autocrine, not paracrine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510120     DOI: 10.1089/thy.1998.8.125

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  15 in total

1.  Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells.

Authors:  S Scarpino; A Stoppacciaro; F Ballerini; M Marchesi; M Prat; M C Stella; S Sozzani; P Allavena; A Mantovani; L P Ruco
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Off-target effects of c-MET inhibitors on thyroid cancer cells.

Authors:  Yan Zhou; Conghui Zhao; Sigal Gery; Glenn D Braunstein; Ryoko Okamoto; Rocio Alvarez; Steven A Miles; Ngan B Doan; Jonathan W Said; Jiang Gu; H Phillip Koeffler
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

3.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

4.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

5.  Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid.

Authors:  Mauro Papotti; Martina Olivero; Marco Volante; Francesco Negro; Maria Prat; Paolo M. Comoglio; Maria Flavia DiRenzo
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

6.  Serum hepatocyte growth factor is increased in Hashimoto's thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals.

Authors:  R M Ruggeri; S Sciacchitano; A Vitale; P Cardelli; M Galletti; E Vitarelli; G Barresi; S Benvenga; F Trimarchi; M Trovato
Journal:  J Endocrinol Invest       Date:  2009-03-25       Impact factor: 4.256

7.  The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization.

Authors:  R M Ruggeri; E Vitarelli; G Barresi; F Trimarchi; S Benvenga; M Trovato
Journal:  Eur J Histochem       Date:  2010-06-03       Impact factor: 3.188

8.  Molecular pathways associated with aggressiveness of papillary thyroid cancer.

Authors:  Salvatore Benvenga; Christian A Koch
Journal:  Curr Genomics       Date:  2014-06       Impact factor: 2.236

Review 9.  Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.

Authors:  Mingxu Guan; Gaetano Romano; Roberta Coroniti; Earl E Henderson
Journal:  J Exp Clin Cancer Res       Date:  2014-11-01

10.  What is New on Thyroid Cancer Biomarkers.

Authors:  Rosaria M Ruggeri; Alfredo Campennì; Sergio Baldari; Francesco Trimarchi; Maria Trovato
Journal:  Biomark Insights       Date:  2008-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.